← Back to Screener
Klotho Neurosciences, Inc. Common Stock (KLTO)
Price$0.42
Favorite Metrics
Price vs S&P 500 (26W)-36.92%
Price vs S&P 500 (4W)-5.76%
Market Capitalization$38.55M
All Metrics
Book Value / Share (Quarterly)$0.14
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.08
Price vs S&P 500 (YTD)41.19%
EPS (TTM)$-0.33
10-Day Avg Trading Volume4.09M
EPS Excl Extra (TTM)$-0.33
EPS (Annual)$-0.32
ROI (Annual)-422.10%
Cash / Share (Quarterly)$0.10
ROA (Last FY)-250.28%
EBITD / Share (TTM)$-0.20
Cash Flow / Share (Annual)$-0.11
P/B Ratio3.88x
P/B Ratio (Quarterly)3.43x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-16.25x
ROA (TTM)-171.30%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)0.13x
Quick Ratio (Quarterly)82.76x
3-Month Avg Trading Volume2.98M
52-Week Price Return151.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.11
52-Week High$3.91
EPS Excl Extra (Annual)$-0.32
26-Week Price Return-28.17%
Quick Ratio (Annual)0.05x
13-Week Price Return39.12%
Total Debt / Equity (Annual)0.23x
Current Ratio (Quarterly)83.69x
Enterprise Value$31.2
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
3-Month Return Std Dev191.28%
Net Income / Employee (TTM)$-4
ROE (Last FY)-518.87%
Net Interest Coverage (Annual)-1.98x
EPS Basic Excl Extra (Annual)$-0.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.33
ROI (TTM)-184.60%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)116.10%
Year-to-Date Return45.33%
5-Day Price Return14.44%
EPS Normalized (Annual)$-0.32
Month-to-Date Return27.27%
EBITD / Share (Annual)$-0.30
LT Debt / Equity (Annual)0.14x
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-0.33
P/TBV (Quarterly)4.47x
P/B Ratio (Annual)8.04x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)36.25%
Beta2.40x
Revenue / Share (TTM)$0.00
ROE (TTM)-201.59%
52-Week Low$0.12
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KLTOKlotho Neurosciences, Inc. Common Stock | — | — | — | — | $0.42 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Klotho Neurosciences develops therapies for cancer, cardiovascular, and neurodegenerative diseases using two platforms: a biosimilar biologics program for oncology and a proprietary gene therapy platform that delivers the Klotho protein to treat neurodegeneration. The company's pipeline includes three development-stage candidates: KLTO 101, KLTO 202, and KLTO 301.